Global Hot Flashes Market Insights, Epidemiology and Market Forecast to 2027

DUBLIN, Sept. 19, 2018 /PRNewswire/ --

The "Hot Flashes - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

Hot Flashes - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hot Flashes in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Hot Flashes from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Hot Flashes - Disease Understanding and Treatment Algorithm

Hot flashes (HF) are often described as episodic sensations of heat, intense sweating, and flushing affecting the face and chest, which are often accompanied by palpitations and anxiety. Each particular episode lasts 3-10 minutes and episodes can recur with varying frequency. Some women experience hot flashes hourly or daily, whereas for others they may occur occasionally. The age at onset of hot flashes also varies from woman to woman. Hot flashes typically begin as the sudden sensation of heat centered on the upper chest and face. When moderate or severe, the hot flash rapidly become generalized, lasts from 2 to 4 minutes, and can be associated with profuse perspiration, palpitations, or anxiety.

The Hot Flashes market report gives the thorough understanding of the Hot Flashes by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hot Flashes in the US, Europe, and Japan.

Hot Flashes Epidemiology

The Hot Flashes epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalent Population of Hot Flashes Associated with Post-menopause and Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause] scenario of Hot Flashes in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According this research, prevalent population of Hot Flashes associated with menopause in 7MM countries is expected to increase at a CAGR of 0.208% for the study period i.e. 2016-2027. As per the estimates, United States has the highest prevalent population of Hot Flashes associated with Post Menopause. Among the European countries, Germany had the highest prevalent population of Hot Flashes with 5,215,367 cases, followed by France which had prevalent population of 3,485,768 in 2016.

Hot Flashes Drug Chapters

This segment of the Hot Flashes report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current therapeutic landscape of Hot Flashes associated with post-menopause can be divided into two major categories based on the class of drug; these are: Hormonal Therapies and Non-Hormonal Therapies. Detailed chapters of upcoming therapies such as TX-001HR (TherapeuticsMD), BHR-401 (Besins Healthcare), Donesta (Mithra Pharmaceuticals), Salubrin (PH-80; Pherin Pharmaceuticals), Fezolinetant (ESN364; Ogeda/Astellas) and NT-814 (Nerre Therapeutics) which are expected to launch during the forecast period [2018-2027] have also been covered in the report.

Hot Flashes Market Outlook

The Hot Flashes market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According this research, the market size of Hot Flashes associated with Post-menopause in the seven major markets is expected to reach around USD 5,755.4 million by 2027. The United States accounts for the highest market size of Hot Flashes associated with Post-menopause in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. The increased risk of Hormonal therapies (Breast Cancer, Dementia, and Cardiovascular Diseases) for the treatment of HF associated with postmenopause led to a decline in prescription Hormonal medication. This has led to a decline in the overall market size for the treatment of HF in the US from 2016 to 2022. However, analysts estimate that the market is expected to show positive growth post 2022, due to the increased patient prevalence and to the expected launch of emerging Hormonal Therapies and targeted non-hormonal therapies.

Hot Flashes Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of Hormonal therapies for Hot Flashes such as TherapeuticsMD (TX-001HR), Besins Healthcare (BHR-401), Mithra Pharmaceuticals (Donesta) and targeted Non-Hormonal Therapies such as Salubrin (PH-80; Pherin Pharmaceuticals), Fezolinetant (ESN364; Ogeda/Astellas) and NT-814 (Nerre Therapeutics) in the forecast period [2018-2027] will also create a positive impact on the Hot Flashes market.

Key Topics Covered:

1. Key Insights

2. Hot Flashes: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Hot Flashes in 2016
2.2. Total Market Share (%) Distribution of Hot Flashes in 2027

3. Hot Flashes associated with menopause: Disease Background and Overview
3.1. Introduction
3.2. Vasomotor Symptoms
3.3. Signs and Symptoms of VMS
3.4. Pathophysiology of VMS
3.5. Risk factors for VMS
3.6. Effects of VMS
3.7. Premature (early) Menopause
3.8. Menopause Associated with Breast Cancer Treatment

4. Epidemiology and Patient Population
4.1. Key Findings

5. Total Prevalent Patient Population of Hot Flashes associated with Post-menopause in 7MM Countries

6. Country Wise-Epidemiology of Hot Flashes Associated with Post-menopause
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Total Prevalent Population of Hot Flashes Associated with Post-menopause in the United States
6.1.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause in the United States
6.2. EU5 Countries
6.3. Germany
6.3.1. Assumptions and Rationale
6.3.2. Total Prevalent Population of Hot Flashes Associated with Postmenopause in Germany
6.3.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause in Germany
6.4. France
6.4.1. Assumptions and Rationale
6.4.2. Total Prevalent Population of Hot Flashes Associated with Post-menopause in France
6.4.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Postmenopause in France
6.5. Italy
6.5.1. Assumptions and Rationale
6.5.2. Total Prevalent Population of Hot Flashes Associated with Postmenopause in Italy
6.5.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Postmenopause in Italy
6.6. Spain
6.6.1. Assumptions and Rationale
6.6.2. Total Prevalent Population of Hot Flashes Associated with Postmenopause in Spain
6.6.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause in Spain
6.7. The United Kingdom
6.7.1. Assumptions and Rationale
6.7.2. Total Prevalent Population of Hot Flashes Associated with Post-menopause in the UK
6.7.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause in the UK
6.8. Japan
6.8.1. Assumptions and Rationale
6.8.2. Total Prevalent Population of Hot Flashes Associated with Post-menopause in Japan
6.8.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause in Japan

7. Treatment Algorithm, Current Treatment, and Medical Practices
7.1. Hormonal Therapies
7.1.1. Estrogen Replacement Therapies
7.1.2. Progestational Agents
7.2. Non-hormonal pharmacological treatments for vasomotor symptoms
7.2.1. Clonidine
7.2.2. Serotonin Reuptake Inhibitors
7.2.3. Gabapentin
7.2.4. Behavioral Modifications
7.3. Complementary alternative medicines (CAM):

8. Unmet Needs

9. Marketed drugs by class
9.1. Hormonal Therapies
9.1.1. Estrogen Only Therapies
9.1.2. Combination Therapies
9.2. Non-Hormonal Therapies
9.2.1. Approved Drug
9.2.2. Off-Label Antidepressants

10. Emerging Therapies
10.1. Key Cross Competition
10.2. TX-001HR: TherapeuticsMD
10.2.1. Product Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. BHR-401 (Utrogestan): Besins Healthcare
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.4. Product Profile
10.4. Prasterone + Acolbifene: Endoceutics
10.4.1. Product Description
10.4.2. Other Developmental Activities
10.4.3. Clinical Development
10.4.4. Product Profile
10.5. MT-8554: Mitsubishi Tanabe Pharma
10.5.1. Product Description
10.5.2. Clinical Development
10.5.3. Product Profile
10.6. ESN364: Ogeda
10.6.1. Product Description
10.6.2. Other Developmental Activities
10.6.3. Clinical Development
10.6.4. Safety and Efficacy
10.6.5. Product Profile
10.7. NT-814: Nerre Therapeutics
10.7.1. Product Description
10.7.2. Other Developmental Activities
10.7.3. Clinical Development
10.7.4. Safety and Efficacy
10.7.5. Advantages and Disadvantages
10.7.6. Product Profile
10.8. Salubrin: Pherin Pharmaceuticals
10.8.1. Product Description
10.8.2. Other Developmental Activities
10.8.3. Clinical Development
10.8.4. Safety and Efficacy
10.8.5. Advantages and Disadvantages
10.8.6. Product Profile
10.9. Donesta: Mithra Pharmaceuticals (Donesta Biosciences)
10.9.1. Product Description
10.9.2. Other Developmental Activities
10.9.3. Clinical Development
10.9.4. Safety and Efficacy
10.9.5. Product Profile
10.10. FP-101: Fervent Pharmaceuticals
10.10.1. Product Description
10.10.2. Other Developmental Activities
10.10.3. Clinical Development
10.10.4. Product Profile
10.11. MLE4901 (AZD4901): Millendo Therapeutics
10.11.1. Product Description
10.11.2. Other Developmental Activities
10.11.3. Clinical Development
10.11.4. Safety and Efficacy
10.11.5. Advantages and Disadvantages
10.11.6. Product Profile

11. Hot Flashes: 7 Major Market Analysis
11.1. Key Findings
11.2. Market Size of Hot Flashes associated with Post Menopause in 7MM
11.3. Market Size by Therapies in 7MM

12. The United States Market Outlook
12.1. United States Market Size
12.2. Total Market size of Hot Flashes in the United States
12.3. Market Size by Therapies in the United States

13. EU-5 Countries: Market Outlook
13.1. Germany: Market Outlook
13.1.1. Total Market size of Hot Flashes in Germany
13.1.2. Market Size by Therapies in Germany
13.2. France: Market Outlook
13.2.1. Total Market size of Hot Flashes in France
13.2.2. Market Size by Therapies in France
13.3. Italy: Market Outlook
13.3.1. Total Market size of Hot Flashes in Italy
13.3.2. Market Size by Therapies in Italy
13.4. Spain: Market Outlook
13.4.1. Total Market Size of Hot Flashes in Spain
13.4.2. Market Size by Therapies in Spain
13.5. United Kingdom: Market Outlook
13.5.1. Total Market size of Hot Flashes in the United Kingdom
13.5.2. Market Size by Therapies in the United Kingdom
13.6. Japan: Market Outlook
13.6.1. Total Market size of Hot Flashes in Japan
13.6.2. Market Size by Therapies in Japan

14. Market Drivers

15. Market Barriers

16. Appendix 

Companies Mentioned

• TherapeuticsMD
• Besins Healthcare
• Endoceutics
• Mitsubishi Tanabe Pharma
• Ogeda
• Nerre Therapeutics
• Pherin Pharmaceuticals
• Mithra Pharmaceuticals,
• Fervent Pharmaceuticals
• Millendo Therapeutics

For more information about this drug pipelines report visit

https://www.researchandmarkets.com/research/x4bfzh/global_hot?w=5

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com